Integra LifeSciences Holdings Corporation
IART
$23.95
$1.345.93%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 442.65M | 380.83M | 418.18M | 368.87M | 397.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 442.65M | 380.83M | 418.18M | 368.87M | 397.04M |
| Cost of Revenue | 176.80M | 162.79M | 167.39M | 149.02M | 157.80M |
| Gross Profit | 265.84M | 218.04M | 250.78M | 219.86M | 239.24M |
| SG&A Expenses | 172.92M | 164.94M | 175.72M | 155.19M | 141.19M |
| Depreciation & Amortization | 3.72M | 3.76M | 3.71M | 3.04M | 3.03M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 378.33M | 355.71M | 371.00M | 328.37M | 320.83M |
| Operating Income | 64.32M | 25.13M | 47.17M | 40.50M | 76.21M |
| Income Before Tax | 22.54M | -20.36M | -15.19M | -5.23M | 28.86M |
| Income Tax Expenses | 3.11M | -9.67M | -2.78M | -1.95M | 9.02M |
| Earnings from Continuing Operations | 19.44M | -10.70M | -12.40M | -3.28M | 19.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.44M | -10.70M | -12.40M | -3.28M | 19.83M |
| EBIT | 64.32M | 25.13M | 47.17M | 40.50M | 76.21M |
| EBITDA | 109.01M | 46.89M | 91.05M | 71.07M | 107.20M |
| EPS Basic | 0.25 | -0.14 | -0.16 | -0.04 | 0.25 |
| Normalized Basic EPS | 0.40 | 0.11 | 0.29 | 0.26 | 0.54 |
| EPS Diluted | 0.25 | -0.14 | -0.16 | -0.04 | 0.25 |
| Normalized Diluted EPS | 0.40 | 0.11 | 0.29 | 0.26 | 0.54 |
| Average Basic Shares Outstanding | 76.42M | 76.45M | 77.41M | 77.74M | 77.96M |
| Average Diluted Shares Outstanding | 76.42M | 76.45M | 77.41M | 77.74M | 77.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
